Development and Validation of a Highly Sensitive LC-MS/MS Method for the Quantification of Gabapentin in Human Plasma: Analytical Method Validation and Application in Bioequivalence Studies
Keywords:
Gabapentin, LC-MS/MS, Plasma quantification, Method validationAbstract
In this study, a novel liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for the quantification of gabapentin in human plasma. The method employed a reverse-phase high-performance liquid chromatography (RP-HPLC) system coupled with an electrospray ionization (ESI) quadrupole mass spectrometer. Analytical method validation (AMV) was performed in compliance with the International Council for Harmonisation (ICH) M10 guidelines and European Medicines Evaluation Agency (EMEA) recommendations. Gabapentin and the internal standard (tramadol) were extracted from plasma samples using a liquid-liquid extraction technique, followed by chromatographic separation on an Agilent ZORBAX SB-C18 column. The method demonstrated excellent specificity, linearity, and precision over a concentration range of 0.2 to 9600 ng/mL. The limit of quantification (LLOQ) for gabapentin was determined to be 20 ng/mL with a signal-to-noise ratio (S/N) greater than 10. The accuracy of the method was assessed by testing at three different concentration levels (low, medium, and high), with deviation percentages (Dev%) of ≤ 5.0%. The method exhibited satisfactory precision, with relative standard deviations (RSD%) ≤ 10%. Cross-validation between between-run and within-run conditions confirmed method robustness and reliability. The method's applicability was demonstrated by its successful use in plasma bioequivalence studies involving gabapentin. Additionally, the carry-over effect was tested to ensure minimal interference in subsequent injections. Overall, the method is highly suitable for pharmacokinetic studies and clinical research requiring precise quantification of gabapentin in human plasma.
Downloads
References
1.
Ali, R. M., et al. (2020). "Development and validation of an LC-MS/MS method for the quantification of gabapentin in human plasma." Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1131, 121828.
2.
Bian, Y., et al. (2020). "A robust LC-MS/MS method for quantification of gabapentin in human plasma and its application in pharmacokinetic studies." Pharmaceutical Analysis, 9(3), 231-238.
3.
Dabezies, C. L., et al. (2021). "Retinal microvascular changes in Alzheimer's disease: A systematic review." Journal of Alzheimer's Disease, 79(4), 1221-1234.
4.
Dumont, F., et al. (2021). "Optimization and validation of a LC-MS/MS method for the quantification of gabapentin in human plasma." Journal of Analytical Toxicology, 45(4), 340-347.
5.
Fischer, S. M., et al. (2021). "Recent advances in LC-MS/MS techniques for bioanalysis." Trends in Analytical Chemistry, 131, 115986.
6.
Liu, W., et al. (2020). "Simultaneous determination of gabapentin and its metabolites in human plasma by liquid chromatography-tandem mass spectrometry." Journal of Pharmaceutical and Biomedical Analysis, 179, 113028.
7.
Mendez, L., et al. (2020). "Comparative study of extraction techniques for the analysis of gabapentin in plasma by LC-MS/MS." Journal of Chromatography A, 1627, 461374.
8.
Smith, M. R., et al. (2020). "LC-MS/MS bioanalysis of gabapentin: Method development, validation, and pharmacokinetic application." Journal of Chromatography B, 1147, 122096.
9.
Wang, Y., et al. (2020). "Retinal microvascular changes as biomarkers of Alzheimer's disease: A review." Neurobiology of Aging, 85, 67-75.
10.
Yeo, L. A., et al. (2020). "A method for the quantification of gabapentin in human plasma using LC-MS/MS for clinical and pharmacokinetic studies." Bioanalysis, 12(13), 873-885.
11.
Zhang, Y., et al. (2021). "Advances in liquid chromatography-tandem mass spectrometry (LC-MS/MS) for therapeutic drug monitoring." Therapeutic Drug Monitoring, 43(1), 37-46
